Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF

Sponsor
French Cardiology Society (Other)
Overall Status
Completed
CT.gov ID
NCT04344327
Collaborator
Institut National de la Santé Et de la Recherche Médicale, France (Other)
2,878
23
11
125.1
346.2

Study Details

Study Description

Brief Summary

The COVID-19 pandemic of SARS CoV2 (Severe Acute Respiratory Syndrome, COVID-19) infection, which is currently evolving in France, raises many questions about the clinical and biological profile of infected hospitalized patients. If certain biological factors like troponin, BNP (Brain Natriuretic Peptid), or clinical factors like cardiovascular history or oncological history are associated with a worse prognosis, available data comes from studies in Asia for the majority, or including a limited number of patients. Patient stratification remains a major issue for patient sorting and early referral of patients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This study is observational, multicenter and retrospective, and is conducted in hospitals in France.

    Clinical data relating to history, comorbidities, risk factors, previous treatments, treatments during the hospitalization and treatments at the discharge from hospital, clinical parameters, biological and ultrasound cardiological data, procedures and events during hospitalization will be recorded, in order to identify the early predictors of clinical worsening in patients hospitalized for COVID-19 in cardiology or conventional medicine department.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    2878 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF
    Actual Study Start Date :
    Apr 10, 2020
    Actual Primary Completion Date :
    Apr 21, 2020
    Actual Study Completion Date :
    Apr 21, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Patients with COVID-19

    Patients hospitalized in conventional sector with diagnosis of COVID-19 (positive PCR (Polymerase Chain Reaction) or diagnosis presumed by the clinical and radiographic picture)

    Outcome Measures

    Primary Outcome Measures

    1. Death rate [Through study completion, an average of 4 weeks]

      Analysis of all-cause death in relation with clinical patient profile

    2. Transfer to intensive care unit [Through study completion, an average of 4 weeks]

      Correlation between clinical patient profile and transfer need to intensive care unit

    3. Ventilation analysis [Through study completion, an average of 4 weeks]

      Type of ventilation procedures needed during the hospitalization (Orotracheal intubation for mechanical ventilation or Non-invasive ventilation or 29/5000 high flow oxygen therapy - Optiflow) in relation with clinical patient profile

    Secondary Outcome Measures

    1. Construction of a predictive score for COVID-19 severe form [Through study completion, an average of 4 weeks]

      Description of clinical and biological patient profile leading to a worse prognosis

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients hospitalized in cardiology unit or medicine conventional sector with diagnosis of COVID-19 (positive PCR (Polymerase Chain Reaction) or diagnosis presumed by the clinical and radiographic picture)
    Exclusion Criteria:
    • Minors

    • Pregnant women

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CHU d'Amiens Amiens France 80054
    2 CHU Annecy Annecy France 74374
    3 CHU de Bordeaux Bordeaux France 33404
    4 CHU de Caen Caen France 14033
    5 Cotentin hospital Cherbourg France 50100
    6 CHU Dijon Dijon France 21079
    7 Elbeuf Louviers Val de Reuil Elbeuf France 76500
    8 CHU de Fréjus / Saint-Raphael Fréjus France 83608
    9 Lille Catholic Institute Hospital Group, Lille Lille France 59000
    10 CHU de Lyon Lyon France 69229
    11 APHM Marseille France 13000
    12 Jacques Cartier Private Hospital, Massy Massy France 91300
    13 CHR d'Orléans Orléans France
    14 Bichat (APHP) Paris France 75000
    15 Georges Pompidou European Hospital (AP-HP) Paris France 75000
    16 Institut Mutualiste Montsouris, Paris Paris France 75000
    17 CHU de Reims Reims France 51092
    18 CHU de Rouen Rouen France 76000
    19 CHU Saint Etienne Saint-Étienne France 42055
    20 CHU de Strasbourg Strasbourg France 67000
    21 CHU de Toulouse Toulouse France 31000
    22 Saint Gatien hospital Tours France 3540
    23 CHU de Nancy Vandœuvre-lès-Nancy France 54500

    Sponsors and Collaborators

    • French Cardiology Society
    • Institut National de la Santé Et de la Recherche Médicale, France

    Investigators

    • Study Director: Guillaume BONNET, MD, Hopital Européen Georges Pompidou
    • Principal Investigator: Orianne WEIZMAN, MD, CHU de Nancy

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    French Cardiology Society
    ClinicalTrials.gov Identifier:
    NCT04344327
    Other Study ID Numbers:
    • 2020-02
    First Posted:
    Apr 14, 2020
    Last Update Posted:
    Apr 28, 2020
    Last Verified:
    Apr 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by French Cardiology Society
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 28, 2020